Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01586611
Title A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer
Recruitment Unknown status
Gender both
Phase Phase III
Variant Requirements No
Sponsors AHS Cancer Control Alberta
Indications

pancreatic adenocarcinoma

Therapies

Gemcitabine

Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab

Age Groups: adult
Covered Countries CAN


No variant requirements are available.